About Us

Biocytogen: Innovative Models to Empower Antibody Discovery

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. With facilities in the US and China, our CRO division provides models and preclinical services to clients around the globe. In addition, we have a scientific team working on in-house research and discovery of novel antibody therapeutics for licensing and co-development partnerships. To learn more about our asset licensing division, clinical subsidiary, and executive leadership, visit the links below:

Our Missions

Our Milestones

Jan 2023
Product Launch
Sept 2022
HKEX Listing
March 2022
June 2021
Phase II
June 2021
New Financing
Sept 2020
August 2020
Biocytogen & Eucure
Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.
May 2020
Clinical Trials
YH001 & YH002 Approved
Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China
March 2020
Platform Launch
RenMice HiTS Platform Launch
RenMice HiTS Platform initiative launched, signifying Biocytogen's transformation to a biotechnology company
January 2020
Clinical Trials
YH002 Clinical Trials Approved in U.S.
Anti-OX40 antibody YH002 was approved for clinical trials in the United States
October 2019
Clinical Trials
YH001 Clinical Trials Approved in U.S.
Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States
August 2019
New Technology
Rise of RenMab
Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
April 2018
Scaling Up
Venture Funding
Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
February 2018
New Sites
Boston & Shanghai Sites
Boston and Shanghai sites opened for business
Company Matures
Haimen Animal Center Opens
Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
Company Expansion
Preclinical Services & New Funding
Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
Mouse Models
New Mouse Models Developed
Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
Gene Editing
ESC/HR Gene Editing Platform
Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer.
Biocytogen Established

Beijng Biocytogen Co., Ltd (Headquarters) established

Back to top